Louise Goodwin
Overview
Explore the profile of Louise Goodwin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
357
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Catto J, Gordon K, Collinson M, Poad H, Twiddy M, Johnson M, et al.
J Clin Oncol
. 2020 Dec;
39(3):202-214.
PMID: 33332191
Purpose: High-grade nonmuscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease. Treatments include intravesical maintenance (mBCG) and radical cystectomy (RC). We wanted to understand whether a randomized trial comparing these...
2.
Reed O, Jubber I, Griffin J, Noon A, Goodwin L, Hussain S, et al.
PLoS One
. 2020 Oct;
15(10):e0239338.
PMID: 33085669
Objectives: Up to 10% of Bladder Cancers may arise following occupational exposure to carcinogens. We hypothesised that different cancer phenotypes reflected different patterns of occupational exposure. Methods: Consecutive participants, with...
3.
Cowell A, Goodwin L, Hare K, Campbell C
Br Dent J
. 2020 Oct;
PMID: 33082522
Objectives To evaluate a dental nurse-led triage system at a private dental practice in England after the cessation of face-to-face care during the COVID-19 pandemic; to assess types of presenting...
4.
Catto J, Khetrapal P, Ambler G, Sarpong R, Khan M, Tan M, et al.
BMJ Open
. 2018 Aug;
8(8):e020500.
PMID: 30093510
Introduction: Bladder cancer (BC) is a common malignancy and one of the most expensive to manage. Radical cystectomy (RC) with pelvic lymphadenectomy is a gold standard treatment for high-risk BC....
5.
Catto J, Khetrapal P, Ambler G, Sarpong R, Potyka I, Khan M, et al.
Eur Urol
. 2018 May;
74(4):531-534.
PMID: 29793815
No abstract available.
6.
Oughton J, Poad H, Twiddy M, Collinson M, Hiley V, Gordon K, et al.
BMJ Open
. 2017 Aug;
7(8):e017913.
PMID: 28801444
Introduction: High-risk non-muscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease that can be difficult to predict. While around 25% of cancers progress to invasion and metastases, the remaining majority...
7.
Rye C, Chessum N, Lamont S, Pike K, Faulder P, Demeritt J, et al.
Medchemcomm
. 2016 Oct;
7(8):1580-1586.
PMID: 27746890
Heat shock factor 1 (HSF1) is a transcription factor that plays key roles in cancer, including providing a mechanism for cell survival under proteotoxic stress. Therefore, inhibition of the HSF1-stress...
8.
Kettle J, Alwan H, Bista M, Breed J, Davies N, Eckersley K, et al.
J Med Chem
. 2016 Feb;
59(6):2346-61.
PMID: 26878898
Recent literature has claimed that inhibition of the enzyme MTH1 can eradicate cancer. MTH1 is one of the "housekeeping" enzymes that are responsible for hydrolyzing damaged nucleotides in cells and...
9.
Kettle J, Ballard P, Bardelle C, Cockerill M, Colclough N, Critchlow S, et al.
J Med Chem
. 2015 Mar;
58(6):2834-44.
PMID: 25738750
Potent and selective inhibitors of Dyrk1B kinase were developed to explore the hypothesis, based on siRNA studies, that Dyrk1B may be a resistance mechanism in cells undergoing a stress response.
10.
Ward R, Brassington C, Breeze A, Caputo A, Critchlow S, Davies G, et al.
J Med Chem
. 2012 Mar;
55(7):3285-306.
PMID: 22417091
Lactate dehydrogenase A (LDHA) catalyzes the conversion of pyruvate to lactate, utilizing NADH as a cofactor. It has been identified as a potential therapeutic target in the area of cancer...